Herbal Medicine Monographs: What Commission E Still Teaches

What the Expanded Commission E book actually was

The 2000 volume was based on The Complete German Commission E Monographs, published in English in 1998. The earlier compilation contained 380 monographs developed from the work of a German expert committee evaluating herbal medicinal products. The expanded book narrowed the focus to more than 100 herbs common in the US market and added colour photographs, background information, quality standards, safety discussion and summaries of clinical research.

The book shows that each entry was designed as a practical profile rather than a simple plant description. It included common and Latin names, pharmacopoeial naming, plant parts used, key constituents, pharmacology, therapeutic uses, contraindications, side effects, pregnancy and lactation information, interactions, dosage, references and additional resources.

Commission E was an early attempt to standardise herbal therapeutic information

Germany established Commission E in the late 1970s to evaluate medicinal herbs and herbal combinations within a drug-regulatory framework. The resulting monographs became influential because they assembled therapeutic indications and safety information in a consistent format at a time when herbal evidence was scattered across pharmacology, traditional practice and clinical literature.

The system was not identical to a modern systematic review. Evidence standards, trial reporting and regulatory expectations have changed substantially since the monographs were produced. Even the later Expanded Commission E book was a synthesis of historical regulatory conclusions plus additional editorial material, not a new set of randomised trials.

A herbal monograph is most useful when it tells you not only what an herb is used for, but what evidence, preparation and safety assumptions sit behind that use.

Monographs separate identity from therapeutic claims

One strength of the monograph format is that it begins with the plant and preparation. Common names can be ambiguous, and closely related species may differ chemically. Botanical identity, plant part, extraction method and dose therefore matter before efficacy can even be discussed.

This remains a central principle in modern herbal regulation. The European Medicines Agency evaluates specific herbal substances and preparations rather than assuming that every product carrying the same common herb name is equivalent. WHO quality-control guidance likewise emphasises identity, purity and contamination control for medicinal plant materials.

Traditional use and clinical evidence are not the same category

Modern European regulation makes this distinction explicit. A traditional-use registration can rely largely on bibliographic evidence of long-standing use and plausible efficacy, provided specified conditions are met, while well-established use requires a stronger body of evidence. EMA states that traditional products must have at least 30 years of medicinal use, including at least 15 years within the European Union.

That framework helps modern readers interpret older monographs. A use may be historically well established without having the same level of support as a contemporary randomised controlled trial. Likewise, a pharmacological mechanism observed in vitro or in animals does not by itself establish a clinically meaningful effect in humans.

Evidence strength varies dramatically from herb to herb

One reason an overall evidence rating for herbal medicine is difficult is that the category contains hundreds of chemically different products and many indications. Some herbs have multiple controlled trials and regulatory assessment reports; others are supported mainly by traditional use, small studies or indirect pharmacology.

The Expanded Commission E volume itself reflected this unevenness by adding clinical-study summaries and comments on the original monographs. That editorial expansion was valuable, but it also means readers must distinguish the official historical Commission E conclusion from later evidence added by the editors.

How major monograph systems differ

Safety sections are as important as the uses section

Herbal products contain pharmacologically active compounds, so safety cannot be inferred from the fact that a product is natural. The Expanded Commission E monographs included contraindications, side effects, pregnancy and lactation information and drug interactions for this reason.

Current NCCIH guidance reaches the same general conclusion. Herbal supplements can interact with medicines, change drug concentrations or add to unwanted effects. St John's wort is a well-established example because it can alter the metabolism of many medicines and can also contribute to serotonin-related adverse effects when combined with some antidepressants.

Interaction evidence is often incomplete

Not every suspected herb-drug interaction is supported by strong clinical data. NCCIH notes that many proposed interactions are based on laboratory studies, animal experiments, pharmacological reasoning or isolated case reports. That uncertainty is especially important for drugs with a narrow therapeutic index, where relatively small concentration changes may have serious consequences.

Product quality can determine whether a monograph applies

A monograph may describe a particular plant part, extract ratio or preparation, while a commercial product uses a different extraction method or concentration. Substituting one for the other can make an efficacy or safety conclusion less reliable.

WHO quality-control guidance also highlights contamination and residues as important risks in herbal medicines. Identity testing, limits for contaminants and appropriate manufacturing controls are therefore part of safe use, not merely technical details for laboratories.

US regulation differs from European medicinal-product regulation

In the United States, many herbal products are sold as dietary supplements rather than approved drugs. FDA requires specified labelling and places important responsibilities on manufacturers, but a dietary supplement generally does not undergo the same premarket demonstration of safety and efficacy as a new drug.

The intended use also matters. FDA explains that a botanical may fall under different regulatory categories depending on how it is marketed: a product intended to treat disease can be regulated as a drug, while an orally consumed botanical marketed to supplement the diet may be regulated as a dietary supplement.

Modern EMA monographs continue the monograph tradition in a different form

The European Medicines Agency's Committee on Herbal Medicinal Products develops EU herbal monographs for substances and preparations used in herbal medicinal products. These monographs include therapeutic uses and safe conditions of use and are supported by assessment reports that explain the evidence considered.

EMA also distinguishes EU monographs from European Pharmacopoeia monographs. The former address medicinal use and safety, while pharmacopoeial monographs primarily set quality specifications. That distinction mirrors an important lesson from Commission E: quality, efficacy and safety are related but separate questions.

WHO monographs add an international public-health perspective

WHO medicinal-plant monographs were developed to provide scientific information on safety, efficacy and quality control, help countries develop their own formularies and support information exchange. They distinguish uses supported by clinical data from uses found in pharmacopoeias or well-established documents and from uses described mainly in traditional medicine.

This layered presentation is especially helpful for avoiding a common error: assuming that inclusion in a monograph means every listed use has the same evidentiary status. The source of support matters as much as the presence of a use statement.

The 2000 book captured a transitional moment

The Expanded Commission E Monographs appeared when herbal products were growing rapidly in the US market and when several international monograph systems were being developed or expanded. Its appendices reflected that context by covering sales data, European phytomedicines, WHO monographs, ESCOP work and the status of Commission E.

The book therefore served both as a therapeutic reference and as a bridge between German regulatory herbal medicine and the US supplement market. Its historical value is substantial, but its age means current readers should not rely on it alone for present-day contraindications, interactions, pregnancy guidance or regulatory status.

How to read an old herbal monograph responsibly

An older monograph is most useful when treated as the starting point for verification rather than the final authority. A reader should identify exactly which plant, plant part and preparation were evaluated and then compare the stated use with current regulatory assessments and recent clinical evidence.

This historical framework is especially useful when a herbal product carries the same plant name but differs in extraction method, plant part or dose from the preparation described in an older monograph. Those differences can change both expected effects and safety considerations. A modern evidence check should therefore match the actual preparation to the evidence rather than assuming that all products derived from one species are interchangeable. That preparation-specific approach preserves the practical value of the Commission E format while avoiding the mistake of treating a historical monograph as a universal endorsement of every contemporary product.

Before applying a monograph to a modern product, check:

• the exact botanical species and plant part;
• whether the preparation and dose match the evidence being cited;
• whether the use is based on clinical trials, traditional use or mainly pharmacological reasoning;
• whether newer safety warnings, contraindications or drug interactions have been identified;
• whether current regulatory guidance differs from the historical Commission E conclusion.

Why Commission E still matters

Commission E helped normalise the idea that medicinal herbs should be documented with the same practical questions clinicians ask about conventional medicines: what is the preparation, what is it used for, what dose is used, what can go wrong and what other medicines might it interact with?

Modern regulatory science has become more explicit about evidence grading, product quality and the limits of traditional-use data, but the underlying monograph structure remains highly recognisable. The lasting lesson is not that every historical herbal claim was proven; it is that herbal medicines require structured evaluation of identity, efficacy, safety and preparation-specific evidence.

Frequently asked questions

What were the Commission E monographs?

Commission E monographs were German expert evaluations of medicinal herbs and herbal combinations. They summarised therapeutic uses, dosage, contraindications, adverse effects, interactions and pharmacological information. The English compilations made those assessments widely accessible, but the monographs reflect the evidence standards and regulatory context of their time.

Does a Commission E approval prove that an herb works by modern standards?

Not necessarily. Commission E used the evidence available at the time, including traditional experience, pharmacology and clinical studies. Modern evidence standards place greater emphasis on systematic reviews, controlled trials and transparent assessment methods. A historical approval should therefore be checked against current evidence for the same preparation and indication.

Why does the exact herbal preparation matter?

Different plant species, plant parts and extraction methods can produce different chemical profiles. A trial of a standardised extract may not apply to a tea, tincture or supplement with another composition. Monograph conclusions are most reliable when the modern product closely matches the preparation and dose that were evaluated.

Can herbal medicines interact with prescription drugs?

Yes. Some herbs can alter drug metabolism, transport or pharmacological effects. St John's wort is a well-established example, but evidence for many other proposed interactions is incomplete. People taking medicines with a narrow therapeutic index should be particularly cautious and should tell their healthcare providers about herbal products they use.

Are herbal supplements regulated the same way as medicines?

No. Regulation depends on jurisdiction and intended use. In the European Union, herbal medicinal products can follow medicinal-product pathways, including traditional-use registration. In the United States, many herbal products are sold as dietary supplements and do not undergo the same premarket efficacy review required for new prescription drugs.

This article is for general information and is not medical advice. It was reviewed for accuracy by a qualified clinician; decisions about your health should be made with your own doctor.